Bioventix PLC
LSE: BVXP.L0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- London Stock Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Peter John Harrison
- Employees
- 17
- Headquarters
- Farnham, United Kingdom
- IPO year
- 2014
- Market cap
- £88.8M
- Website
- https://www.bioventix.com
Loading BVXP…
Loading profile data…Frequently asked questions about BVXP
What does Bioventix PLC (BVXP.L) do?
Bioventix PLC creates, manufactures, and supplies sheep monoclonal antibodies (SMAs) for diagnostic applications worldwide. The company offers a portfolio of purified SMAs for thyroid, vitamin D, cardiac, drugs of abuse, fertility, infectious disease, oncology, and miscellaneous indications. It also provides contract SMAs and recombinant service...
Where does BVXP.L trade?
Bioventix PLC (BVXP.L) trades on the London Stock Exchange.
What sector is BVXP.L in?
Bioventix PLC (BVXP.L) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Bioventix PLC?
Peter John Harrison is the chief executive officer of Bioventix PLC (BVXP.L).
Where is Bioventix PLC headquartered?
Bioventix PLC is headquartered in United Kingdom.
Does BVXP.L pay a dividend?
Yes — Bioventix PLC (BVXP.L) paid a trailing twelve-month dividend of GBp 150.00 per share. Frequency and ex-dividend dates are tracked on the dividends tab.
When did BVXP.L go public?
Bioventix PLC (BVXP.L) completed its initial public offering in 2014.